Zomedica Pharma (ZOM) has released an update.
Zomedica Corp. reported a robust start to 2024 with a 14% increase in first-quarter revenue to $6.3 million and a solid gross margin of 66%. The growth was attributed to a strong performance in both Therapeutic Devices and Diagnostics segments, with the company touting the period as its strongest first quarter ever. Despite a total cash usage of $9.6 million, Zomedica is optimistic about its expansion strategy and is on track to pursue profitability and significant revenue growth.
For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.
